ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 08/06/22
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 StudyBusiness Wire • 08/01/22
AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilienceProactive Investors • 07/29/22
LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 07/27/22
AstraZeneca: Q2 2022 Earnings May Not Wow Investors - Steady Growth's The CharmSeeking Alpha • 07/25/22
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast CancerBusiness Wire • 07/25/22
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer StudyBenzinga • 07/19/22
ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensBusiness Wire • 07/19/22